Literature DB >> 22350776

Target delivery and controlled release of the chemopreventive drug sulindac by using an advanced layered double hydroxide nanomatrix formulation system.

Keiji Minagawa1, Mohamed R Berber, Inas H Hafez, Takeshi Mori, Masami Tanaka.   

Abstract

Target delivery and controlled release of the chemopreventive drug sulindac that possesses low water solubility present a great challenge for its pharmaceutical industry. Here, we offered an advanced nanomatrix formulation system of sulindac based on layered double hydroxide materials. The X-ray analysis and infrared spectroscopy confirmed the incorporation of sulindac into the gallery of the layered double hydroxides. The incorporation ratios of sulindac were recorded to be 45, 31 and 20 for coprecipitation, anion-exchange and reconstruction techniques, respectively. The scanning electron microscopy showed a nanomatrix-structure of ~50 nm. The release studies of sulindac-nanomatrix showed a 96% controlled release at the small intestine solution during 3 h(s), indicating an enhancement in the dissolution profile of sulindac after the matrix formation. The layered structure of the matrix supplied sulindac with a well-ordered structure and a relatively hydrophobic microenvironment that controlled the guest hydrolysis and reactivity during the release process. The laminar structure of layered double hydroxides offered a safe preservation for sulindac against photodecarboxylation, and enhanced the drug thermal stability from 190 to 230° C. The ionic electrostatic interaction of sulindac through its acidic group with layered double hydroxides demolished the gastrointestinal ulceration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350776     DOI: 10.1007/s10856-012-4566-x

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  23 in total

1.  Zn-Al-NO(3)-layered double hydroxides with intercalated diclofenac for ocular delivery.

Authors:  Feng Cao; Yanjun Wang; Qineng Ping; Zhenggen Liao
Journal:  Int J Pharm       Date:  2010-11-17       Impact factor: 5.875

2.  An artificial stomach-duodenum model for the in-vitro evaluation of antacids.

Authors:  J Vatier; E Malikova-Sekera; M T Vitre; M Mignon
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

3.  Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.

Authors:  Jin Kyung Lee; Mary F Paine; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

Review 4.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

5.  Characterization of hemoglobin immobilized in MgAl-layered double hydroxides by the coprecipitation method.

Authors:  Khaled Charradi; Claude Forano; Vanessa Prevot; Dominique Madern; Abdesslem Ben Haj Amara; Christine Mousty
Journal:  Langmuir       Date:  2010-06-15       Impact factor: 3.882

Review 6.  Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy.

Authors:  Barry Schlansky; Joo Ha Hwang
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Comparative bioavailability of sulindac in capsule and tablet formulations.

Authors:  Joel M Reid; Sumithra J Mandrekar; Elsa C Carlson; W Scott Harmsen; Erin M Green; Renee M McGovern; Eva Szabo; Matthew M Ames; Daniel Boring; Paul J Limburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

8.  Mg-Al layered double hydroxide intercalated with porphyrin anions: molecular simulations and experiments.

Authors:  Petr Kovár; Miroslav Pospísil; Eva Káfunková; Kamil Lang; Frantisek Kovanda
Journal:  J Mol Model       Date:  2009-07-03       Impact factor: 1.810

9.  Solubilization and interaction of sulindac with polyvinylpyrrolidone K30 in the solid state and in aqueous solution.

Authors:  M C Tros de Ilarduya; C Martín; M M Goñi; M C Martínez-Ohárriz
Journal:  Drug Dev Ind Pharm       Date:  1998-03       Impact factor: 3.225

10.  Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation.

Authors:  Nilüfer Yüksel; Aysegül Karataş; Yalçin Ozkan; Ayhan Savaşer; Sibel A Ozkan; Tamer Baykara
Journal:  Eur J Pharm Biopharm       Date:  2003-11       Impact factor: 5.571

View more
  3 in total

1.  Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.

Authors:  Yang Guo; Ting Zhong; Xiao-Chuan Duan; Shuang Zhang; Xin Yao; Yi-Fan Yin; Dan Huang; Wei Ren; Qiang Zhang; Xuan Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  Controlled release of organic-inorganic nanohybrid:cefadroxil intercalated Zn-Al-layered double hydroxide.

Authors:  Sher Bahadar Khan; Khalid A Alamry; Nedaa A Alyahyawi; Abdullah M Asiri
Journal:  Int J Nanomedicine       Date:  2018-05-29

3.  Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines.

Authors:  Samer Hasan Hussein Al Ali; Mothanna Al-Qubaisi; Mohd Zobir Hussein; Maznah Ismail; Saifullah Bullo
Journal:  Drug Des Devel Ther       Date:  2013-01-14       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.